View Filing Data



	Three Months Ended March 31,
	2020			2019
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest	$	80.0		$	99.7
Income taxes, net of refunds	5.8			(2.2		)
Disclosure of non-cash financing and investing activities:
Conversion of zero-coupon convertible debt	—			7.3
Change in accrued property, plant and equipment	(14.0		)	(12.1		)

Business Combination Disclosure [Text Block]

SUPPLEMENTAL CASH FLOW INFORMATION



	Three Months Ended March 31,
	2020			2019
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest	$	80.0		$	99.7
Income taxes, net of refunds	5.8			(2.2		)
Disclosure of non-cash financing and investing activities:
Conversion of zero-coupon convertible debt	—			7.3
Change in accrued property, plant and equipment	(14.0		)	(12.1		)

BUSINESS ACQUISITIONS

3 Months Ended

Mar. 31, 2020

Business Combinations [Abstract]

BUSINESS ACQUISITIONS AND DISPOSITIONS

On June 3, 2019, CDD acquired Envigo's nonclinical contract research services business, expanding CDD's global nonclinical drug development capabilities with additional locations and resources. Additionally, the Company divested the Covance Research Products (CRP) business, which was a part of CDD, to Envigo. As part of this sale, CDD entered into a multi-year, renewable supply agreement with Envigo. The Company paid cash consideration of $601.0, received a floating rate secured note of $110.0, and recorded a loss on the sale of CRP of $12.2. The Company funded the transaction through a new term loan facility.

The preliminary valuation of acquired assets and assumed liabilities in the transaction as of June 3, 2019, include the following:



Consideration Transferred
Cash consideration	$	601.0
Fair value of CRP	110.0
Total	$	711.0

	Preliminary June 30, 2019		Measurement Period Adjustments			Preliminary March 31, 2020
Net Assets Acquired
Cash and cash equivalents	$	15.1	$	(3.7	)	$	11.4
Accounts receivable	16.5		(4.6		)	11.9
Unbilled services	26.5		(0.3		)	26.2
Inventories	4.5		—			4.5
Prepaid expenses and other	3.5		6.3			9.8
Property, plant and equipment (including ROU operating lease assets)	99.1		25.8			124.9
Deferred income taxes	25.5		(11.5		)	14.0
Goodwill	432.2		(51.4		)	380.8
Customer relationships	125.8		15.0			140.8
Trade name and trademarks	0.6		—			0.6
Other assets	9.9		—			9.9
Total assets acquired	759.2		(24.4		)	734.8
Accounts payable	15.4		(0.2		)	15.2
Accrued expenses and other	11.6		(1.5		)	10.1
Unearned revenue	49.9		—			49.9
Operating lease liabilities	15.0		(15.0		)	—
Other liabilities	66.3		(7.7		)	58.6
Total liabilities acquired	158.2		(24.4		)	133.8
Net Envigo assets acquired	601.0		$	—		$	601.0
Floating rate secured note receivable due 2022	110.0
Total	$	711.0

The preliminary purchase consideration for Envigo has been allocated to the estimated fair market value of the net assets acquired, including approximately $141.4 in identifiable intangible assets and a residual amount of non-tax-deductible goodwill of approximately $380.8. The amortization period for intangible assets acquired is 11 years for customer relationships.

The purchase price allocation for the Envigo transaction is still preliminary and subject to change. The areas of the purchase price allocation that are not yet finalized relate primarily to goodwill and the impact of finalizing deferred taxes. Accordingly, adjustments may be made as additional information is obtained about the facts and circumstances that existed as of the valuation date. The Company expects these purchase price allocations to be finalized by the second quarter of 2020. Any adjustments will be recorded in the period in which they are identified.

During the three months ended March 31, 2020, the Company recorded a $5.0 charge for the estimated credit loss related to the CDD floating rate secured note receivable due 2022 from Envigo.

During the three months ended March 31, 2019, the Company acquired various businesses and related assets for approximately $47.3 in cash (net of cash acquired). The purchase consideration for all acquisitions in that period has been allocated to the estimated fair market value of the net assets acquired, including approximately $24.8 in identifiable intangible assets and a residual amount of goodwill of approximately $22.1. These acquisitions were made primarily to extend the Company's geographic reach in important market areas, enhance the Company's scientific differentiation and to expand the breadth and scope of the Company's CRO services.

Unaudited Pro Forma Information

Had the Company's total 2019 acquisitions been completed as of January 1, 2019, the Company's pro forma results would have been as follows:



	Three Months Ended March 31, 2019
Revenues	$	2,832.6
Net earnings attributable to Laboratory Corporation of America Holdings	$	188.0

BUSINESS SEGMENT INFORMATION Business Segment information (Notes)

3 Months Ended

Mar. 31, 2020

Segment Reporting Information [Line Items]

Segment Reporting Disclosure [Text Block]

BUSINESS SEGMENT INFORMATION

The following table is a summary of segment information for the three months ended March 31, 2020, and 2019. The management approach has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Company’s chief executive officer has been identified as the CODM.

Segment asset information is not presented because it is not used by the CODM at the segment level. Operating earnings of each segment represents revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses are included in general corporate expenses below.



	Three Months Ended
	March 31,
	2020			2019
Revenues:
LCD	$	1,702.0		$	1,722.0
CDD	1,143.8			1,074.7
Intercompany eliminations and other	(22.0		)	(5.5		)
Revenues	2,823.8			2,791.2

Operating earnings (loss):
LCD	188.4			268.3
CDD	(338.7		)	88.0
General corporate expenses	(42.3		)	(38.1		)
Total operating income (loss)	(192.6		)	318.2
Non-operating expenses, net	(75.1		)	(63.5		)
Earnings (loss) before income taxes	(267.7		)	254.7
Provision for income taxes	49.2			68.8
Net earnings (loss)	(316.9		)	185.9
Less net income attributable to noncontrolling interests	(0.3		)	(0.3		)
Net income (loss) attributable to Laboratory Corporation of America Holdings	$	(317.2	)	$	185.6

BASIS OF FINANCIAL STATEMENT PRESENTATION Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s implicit price concessions and credit losses, equity investments, software, notes receivable and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.

BASIS OF FINANCIAL STATEMENT PRESENTATION New Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Pronouncements In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on defined benefit pension and other postretirement plans. The standard is effective on January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In December 2019, the FASB issued a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In January 2020, the FASB issued a new accounting standard to clarify the interaction of the accounting for equity securities and investments accounted for under the equity method of accounting and the accounting for certain forward contracts and purchased options. The standard is effective January 1, 2021. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In March 2020, the FASB issued a new accounting standard to provide optional expedients and exceptions if certain conditions are met for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The expedients and exceptions in the standard are effective between March 12, 2020 and December 31, 2022. The Company did not elect to apply any of the expedients or exceptions for the period ended March 31, 2020 and is currently evaluating the impact this new standard will have on the consolidated financial statements.

BASIS OF FINANCIAL STATEMENT PRESENTATION Novel Coronavirus (COVID-19) Financial Statement Impact (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Novel Coranvirus (Covid-19) Financial Statement Impact [Policy Text Block]	Novel Coronavirus (COVID-19) Financial Statement Impact In March 2020, the novel strain of coronavirus, now known as COVID-19, was declared a pandemic. The COVID-19 pandemic has and continues to have an extensive impact on the global health and economic environments. By mid-March 2020, government restrictions, social distancing guidelines, and overall customer caution associated with the COVID-19 pandemic negatively affected LCD’s revenues and CDD's operations. For LCD, reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. This reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. The performance of CDD has also been negatively affected by the COVID-19 pandemic through numerous study site closures around the world as well as customer initiated delays for new patient recruitment for existing clinical trials and start-up of new clinical trials. As a result of the impact of the COVID-19 pandemic, during the three months ended March 31, 2020, the Company recorded goodwill and other asset impairment charges of $437.4: $426.4 within CDD and $11.0 within LCD. See Note 6 Goodwill and Intangible Assets for discussion of goodwill and intangible asset impairment and Note 2 Revenue for the discussion of credit losses and additional price concessions. The Company also wrote-off or wrote down certain of the Company's investments by $20.2 due to the impact of COVID-19, $7.1 included in Equity method earnings (loss), net and $13.1 included in Other, net.

BASIS OF FINANCIAL STATEMENT PRESENTATION Recently Adopted Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Recently Adopted Accounting Guidance [Policy Text Block]	Recently Adopted Guidance In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current generally accepted accounting principles (GAAP) with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company recorded an opening retained earnings adjustment of $7.0 with the adoption of this standard on January 1, 2020. In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on fair value measurements. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements.

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Reconciliation of Basic earnings per Share to Diluted Earnings per Share

The following represents a reconciliation of basic earnings (loss) per share to diluted earnings (loss) per share:



	Three Months Ended March 31,
	2020							2019
	Earnings (Loss)			Shares	Per Share Amount			Earnings		Shares	Per Share Amount
Basic earnings (loss) per share:
Net earnings (loss)	$	(317.2	)	97.2	$	(3.27	)	$	185.6	98.6	$	1.88
Dilutive effect of employee stock options and awards	—			—				—		0.9
Net earnings (loss) including impact of dilutive adjustments ^(a)	$	(317.2	)	97.2	$	(3.27	)	$	185.6	99.5	$	1.86

Potential common shares not included in computation of diluted earnings per share

The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:



	Three Months Ended March 31,
	2020	2019
Employee stock options and awards	1.3	0.3

RESTRUCTURING AND OTHER SPECIAL CHARGES Restructuring and Other Special Charges Detail (Tables)

3 Months Ended

Mar. 31, 2020

Restructuring Cost and Reserve [Line Items]

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following represents the Company’s restructuring reserve activities for the period indicated:



	LCD						CDD
	Severance and Other Employee Costs			Facility Costs			Severance and Other Employee Costs			Facility Costs			Total
Balance as of December 31, 2019	$	0.5		$	2.7		$	5.5		$	4.7		$	13.4
Restructuring charges	2.1			1.5			2.5			2.7			8.8
Adjustments to prior restructuring accruals	(0.1		)	(0.2		)	0.6			—			0.3
Impairment of lab facility	—			—			—			4.7			4.7
Impairment of operating lease right-of-use asset	—			4.8			—			6.8			11.6
Cash payments and other adjustments	(0.3		)	(8.7		)	(4.4		)	(12.2		)	(25.6		)
Balance as of March 31, 2020	$	2.2		$	0.1		$	4.2		$	6.7		$	13.2
Current													$	7.8
Non-current													5.4
													$	13.2

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the nine months ended March 31, 2020, are as follows:



	LCD			CDD			Total
Balance as of January 1, 2020	$	3,721.5		$	4,143.5		$	7,865.0
Impairment	(3.7		)	(418.7		)	(422.4		)
Foreign currency impact and other adjustments to goodwill	(6.6		)	(47.5		)	(54.1		)
Balance as of March 31, 2020	$	3,711.2		$	3,677.3		$	7,388.5

Schedule of Intangible Assets and Goodwill [Table Text Block]

The components of identifiable intangible assets are as follows:



	March 31, 2020							December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Customer relationships	$	4,414.4	$	(1,371.0	)	$	3,043.4	$	4,441.7	$	(1,329.5	)	$	3,112.2
Patents, licenses and technology	444.4		(238.7		)	205.7		453.6		(235.7		)	217.9
Non-compete agreements	90.7		(62.3		)	28.4		90.9		(60.5		)	30.4
Trade name	407.3		(228.8		)	178.5		408.2		(219.9		)	188.3
Land use right	10.8		(5.8		)	5.0		10.9		(5.5		)	5.4
Canadian licenses	444.1		—			444.1		480.3		—			480.3
	$	5,811.7	$	(1,906.6	)	$	3,905.1	$	5,885.6	$	(1,851.1	)	$	4,034.5

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Company's population of financial assets and liabilities subject to fair value measurements

The Company’s population of financial assets and liabilities subject to fair value measurements as of March 31, 2020, and December 31, 2019, is as follows:



				Fair Value Measurements as of
		Fair Value as of		March 31, 2020
	Balance Sheet	Fair Value as of		Using Fair Value Hierarchy
	Classification	March 31, 2020		Level 1		Level 2		Level 3
Noncontrolling interest put	Noncontrolling interest	$	14.6	$	—	$	14.6	$	—
Cross currency swaps	Other assets, net	23.1		—		23.1		—
Interest rate swaps	Other assets, net	3.3		—		3.3		—
Cash surrender value of life insurance policies	Other assets, net	68.0		—		68.0		—
Deferred compensation liability	Other liabilities	66.7		—		66.7		—
Contingent consideration	Other liabilities	6.4		—		—		6.4



				Fair Value Measurements as of
		Fair Value as of		December 31, 2019
	Balance Sheet	Fair Value as of		Using Fair Value Hierarchy
	Classification	December 31, 2019		Level 1		Level 2		Level 3
Noncontrolling interest put	Noncontrolling interest	$	15.8	$	—	$	15.8	$	—
Cross currency swaps	Other assets, net	3.2		—		3.2		—
Interest rate swaps	Other assets, net	1.5		—		1.5		—
Cash surrender value of life insurance policies	Other assets, net	80.2		—		80.2		—
Deferred compensation liability	Other liabilities	76.7		—		76.7		—
Investment in equity securities	Other current assets	9.1		9.1		—		—
Contingent consideration	Other liabilities	9.9		—		—		9.9

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]



Fair Value Measurement of Level 3 Liabilities	Contingent Consideration
Balance at December 31, 2019	$	9.9
Payments	(1.4		)
Adjustments	(2.1		)
Balance at March 31, 2020	$	6.4

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)

3 Months Ended

Mar. 31, 2020

Supplemental Cash Flow Information [Abstract]



	Three Months Ended March 31,
	2020			2019
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest	$	80.0		$	99.7
Income taxes, net of refunds	5.8			(2.2		)
Disclosure of non-cash financing and investing activities:
Conversion of zero-coupon convertible debt	—			7.3
Change in accrued property, plant and equipment	(14.0		)	(12.1		)

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

SUPPLEMENTAL CASH FLOW INFORMATION



	Three Months Ended March 31,
	2020			2019
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest	$	80.0		$	99.7
Income taxes, net of refunds	5.8			(2.2		)
Disclosure of non-cash financing and investing activities:
Conversion of zero-coupon convertible debt	—			7.3
Change in accrued property, plant and equipment	(14.0		)	(12.1		)

BUSINESS ACQUISITIONS Business Acquisitions Tables (Tables)

3 Months Ended

Mar. 31, 2020

Business Acquisition [Line Items]

The preliminary valuation of acquired assets and assumed liabilities in the transaction as of June 3, 2019, include the following:



Consideration Transferred
Cash consideration	$	601.0
Fair value of CRP	110.0
Total	$	711.0

	Preliminary June 30, 2019		Measurement Period Adjustments			Preliminary March 31, 2020
Net Assets Acquired
Cash and cash equivalents	$	15.1	$	(3.7	)	$	11.4
Accounts receivable	16.5		(4.6		)	11.9
Unbilled services	26.5		(0.3		)	26.2
Inventories	4.5		—			4.5
Prepaid expenses and other	3.5		6.3			9.8
Property, plant and equipment (including ROU operating lease assets)	99.1		25.8			124.9
Deferred income taxes	25.5		(11.5		)	14.0
Goodwill	432.2		(51.4		)	380.8
Customer relationships	125.8		15.0			140.8
Trade name and trademarks	0.6		—			0.6
Other assets	9.9		—			9.9
Total assets acquired	759.2		(24.4		)	734.8
Accounts payable	15.4		(0.2		)	15.2
Accrued expenses and other	11.6		(1.5		)	10.1
Unearned revenue	49.9		—			49.9
Operating lease liabilities	15.0		(15.0		)	—
Other liabilities	66.3		(7.7		)	58.6
Total liabilities acquired	158.2		(24.4		)	133.8
Net Envigo assets acquired	601.0		$	—		$	601.0
Floating rate secured note receivable due 2022	110.0
Total	$	711.0

Business Acquisition, Pro Forma Information [Table Text Block]

Unaudited Pro Forma Information

Had the Company's total 2019 acquisitions been completed as of January 1, 2019, the Company's pro forma results would have been as follows:



	Three Months Ended March 31, 2019
Revenues	$	2,832.6
Net earnings attributable to Laboratory Corporation of America Holdings	$	188.0

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]



	Carrying amount of hedged liabilities as of				Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liabilities as of
	March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019
Balance Sheet Line Item in which Hedged Items are Included
Current portion, long term debt	$	303.3	$	301.5	$	3.3	$	1.5

BUSINESS SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reconciliation of Operating Income to Consolidated [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]



	Three Months Ended
	March 31,
	2020			2019
Revenues:
LCD	$	1,702.0		$	1,722.0
CDD	1,143.8			1,074.7
Intercompany eliminations and other	(22.0		)	(5.5		)
Revenues	2,823.8			2,791.2

Operating earnings (loss):
LCD	188.4			268.3
CDD	(338.7		)	88.0
General corporate expenses	(42.3		)	(38.1		)
Total operating income (loss)	(192.6		)	318.2
Non-operating expenses, net	(75.1		)	(63.5		)
Earnings (loss) before income taxes	(267.7		)	254.7
Provision for income taxes	49.2			68.8
Net earnings (loss)	(316.9		)	185.9
Less net income attributable to noncontrolling interests	(0.3		)	(0.3		)
Net income (loss) attributable to Laboratory Corporation of America Holdings	$	(317.2	)	$	185.6

REVENUE (Tables)

3 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the three months ended March 31, 2020 is as follows:



	For the Three Months Ended March 31, 2020
	Accounts Receivable		Unbilled Services		Note Receivable		Total
Allowance for credit losses as of December 31, 2019	$	19.0	$	2.3	$	—	$	21.3
Current expected credit losses opening balance impact on retained earnings	1.8		0.2		5.0		7.0
Plus, credit loss expense	8.5		—		5.0		13.5
Less, write offs	0.4		0.1		—		0.5
Ending allowance for credit losses	$	28.9	$	2.4	$	10.0	$	41.3

Contract with Customer, Asset and Liability [Table Text Block]



	March 31, 2020		December 31, 2019
Receivables, which are included in accounts receivable	$	758.6	$	771.1
Unbilled services	480.6		483.7
Unearned revenue	430.9		449.2

Revenue from Contract with Customer [Text Block]

REVENUES

The Company's revenues by segment payers/customer groups for the three months ended March 31, 2020, and 2019, are as follows:



	For the Three Months Ended March 31, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	57	%	3	%	—	%	—	%	—	%	—	%	60	%

CDD
Biopharmaceutical and medical device companies	20	%	—	%	5	%	5	%	3	%	7	%	40	%

Total revenues	77	%	3	%	5	%	5	%	3	%	7	%	100	%



	For the Three Months Ended March 31, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	9	%	—	%	—	%	—	%	—	%	—	%	9	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	59	%	3	%	—	%	—	%	—	%	—	%	62	%

CDD
Biopharmaceutical and medical device companies	19	%	—	%	4	%	5	%	3	%	7	%	38	%

Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

Contract costs

CDD incurs sales commissions in the process of obtaining contracts with customers, which are recoverable through the service fees in the contract. Sales commissions that are payable upon contract award are recognized as assets and amortized over the expected contract term, along with related payroll tax expense. The amortization of commission expense is based on the weighted average contract duration for all commissionable awards in the respective business in which the commission expense is paid, which approximates the period over which goods and services are transferred to the customer. The amortization period of sales commissions ranges from approximately 12 to 57 months, depending on the business. For businesses that enter into primarily short-term contracts, the Company applies the practical expedient, which allows costs to obtain a contract to be expensed when incurred if the amortization period of the assets that would otherwise have been recognized is one year or less. Amortization of assets from sales commissions is included in selling, general, and administrative expense.

CDD incurs costs to fulfill contracts with customers, which are recoverable through the service fees in the contract. Contract fulfillment costs include software implementation costs and setup costs for certain market access solutions. These costs are recognized as assets and amortized over the expected term of the contract to which the implementation relates, which is the period over which services are expected to be provided to the customer. This period typically ranges from 24 to 60 months. Amortization of deferred contract fulfillment costs is included in cost of goods sold.



	March 31, 2020		December 31, 2019
Sales commission assets	$	30.3	$	28.6
Deferred contract fulfillment costs	13.8		14.9
Total	$	44.1	$	43.5

Amortization related to sales commission assets and associated payroll taxes for the three months ended March 31, 2020, and 2019, was $5.3 and $4.5, respectively. Amortization related to deferred contract fulfillment costs for the three months ended March 31, 2020, and 2019, was $3.0 and $1.8, respectively.

Receivables, Unbilled Services and Unearned Revenue

Unbilled services are comprised primarily of unbilled receivables, but also include contract assets. A contract asset is recorded when a right to payment has been earned for work performed, but billing and payment for that work is determined by certain contractual milestones, whereas unbilled receivables are billable upon the passage of time. While CDD attempts to negotiate terms that provide for billing and payment of services prior or in close proximity to the provision of services, this is not always possible and there are fluctuations in the level of unbilled services and unearned revenue from period to period. The following table provides information about receivables, unbilled services, and unearned revenue (contract liabilities) from contracts with customers for CDD.



	March 31, 2020		December 31, 2019
Receivables, which are included in accounts receivable	$	758.6	$	771.1
Unbilled services	480.6		483.7
Unearned revenue	430.9		449.2

Revenues recognized during the period, that were included in the unearned revenue balance at the beginning of the period for the three months ended March 31, 2020 and March 31, 2019 was $121.8 and $103.6, respectively.

Credit Loss Rollforward

With the adoption of current expected credit loss standard in 2020, the Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the three months ended March 31, 2020 is as follows:



	For the Three Months Ended March 31, 2020
	Accounts Receivable		Unbilled Services		Note Receivable		Total
Allowance for credit losses as of December 31, 2019	$	19.0	$	2.3	$	—	$	21.3
Current expected credit losses opening balance impact on retained earnings	1.8		0.2		5.0		7.0
Plus, credit loss expense	8.5		—		5.0		13.5
Less, write offs	0.4		0.1		—		0.5
Ending allowance for credit losses	$	28.9	$	2.4	$	10.0	$	41.3

The note receivable is the floating note receivable due 2022 from the Envigo transaction which is recorded in Other assets, net.

During the three months ended, March 31, 2020, the Company also recorded $17.0 of additional implicit price concessions as a result of anticipated collection challenges from the economic decline.

Performance Obligations Under Long-Term Contracts

Long-term contracts at the Company consist primarily of fully managed clinical studies within CDD. The amount of existing performance obligations under such long-term contracts unsatisfied as of March 31, 2020, was $4,494.9. The Company expects to recognize approximately 35% of the remaining performance obligations as of March 31, 2020 as revenue over the next 12 months, and the balance thereafter. The Company's long-term contracts generally range from 1 to 8 years.

Within CDD, revenues of $9.7 and $39.7 were recognized during the three months ended March 31, 2020, and 2019, respectively, from performance obligations that were satisfied in previous periods. This revenue comes from adjustments related to changes in scope and estimates in full service clinical studies.

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment payers/customer groups for the three months ended March 31, 2020, and 2019, are as follows:



	For the Three Months Ended March 31, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	57	%	3	%	—	%	—	%	—	%	—	%	60	%

CDD
Biopharmaceutical and medical device companies	20	%	—	%	5	%	5	%	3	%	7	%	40	%

Total revenues	77	%	3	%	5	%	5	%	3	%	7	%	100	%



	For the Three Months Ended March 31, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	9	%	—	%	—	%	—	%	—	%	—	%	9	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	59	%	3	%	—	%	—	%	—	%	—	%	62	%

CDD
Biopharmaceutical and medical device companies	19	%	—	%	4	%	5	%	3	%	7	%	38	%

Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

Capitalized Contract Cost [Table Text Block]



	March 31, 2020		December 31, 2019
Sales commission assets	$	30.3	$	28.6
Deferred contract fulfillment costs	13.8		14.9
Total	$	44.1	$	43.5

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Line of Credit Facility, Fair Value of Amount Outstanding

SUPPLEMENTAL CASH FLOW INFORMATION



	Three Months Ended March 31,
	2020			2019
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest	$	80.0		$	99.7
Income taxes, net of refunds	5.8			(2.2		)
Disclosure of non-cash financing and investing activities:
Conversion of zero-coupon convertible debt	—			7.3
Change in accrued property, plant and equipment	(14.0		)	(12.1		)

BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Asset Impairment Charges	$ 437.4	$ 0.0
Revenues	2,823.8	2,791.2
Cost of Revenue	2,095.8	2,001.5
Contract with Customer, Liability	430.9		$ 449.2
Amortization of Deferred Sales Commissions	5.3	4.5
Assets, Current	2,891.1		2,981.2
Net Cash Provided by (Used in) Operating Activities	$ 203.8	$ 165.8
Percent of Revenue Contributed	100.00%	100.00%
Selling, general and administrative expenses	$ 395.5	$ 393.8
Nonoperating Income (Expense)	(75.1)	(63.5)
Provision for income taxes	49.2	68.8
Net earnings	(316.9)	185.9
Net Income (Loss) Attributable to Parent	$ (317.2)	$ 185.6
Basic earnings per common share (in dollars per share)	$ (3.27)	$ 1.88
Diluted earnings per common share (in dollars per share)	$ (3.27)	$ 1.86
Net Cash Provided by (Used in) Investing Activities	$ (106.6)	$ (140.5)
Net Cash Provided by (Used in) Financing Activities	(102.8)	(103.2)
Effect of exchange rate changes on cash and cash equivalents	(8.3)	(0.1)
Assets	17,298.4		18,046.4
Long-term debt, less current portion	2,458.0		2,655.8
Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively	18.5		20.1
Stockholders' Equity Attributable to Parent	7,020.1	7,111.3	7,567.0	$ 6,971.4
Liabilities and Equity	17,298.4		18,046.4
Capitalized Contract Cost, Amortization	3.0	1.8
Deferred Revenue, Revenue Recognized	121.8	103.6
Revenue, Remaining Performance Obligation, Amount	4,494.9
Contract with Customer, Performance Obligation Satisfied in Previous Period	9.7	39.7
Goodwill, Impairment Loss	422.4
Other than Temporary Impairment Losses, Investments	$ 20.2
Ownership percentage below which investments are generally accounted for on the cost method (in thousandths)	20.00%
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			(7.0)
LabCorp Diagnostics [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 1,702.0	$ 1,722.0
Percent of Revenue Contributed	60.00%	62.00%
Goodwill and Intangible Asset Impairment	$ 11.0
Goodwill, Impairment Loss	3.7
Covance Drug Development [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 1,143.8	$ 1,074.7
Percent of Revenue Contributed	40.00%
Goodwill and Intangible Asset Impairment	$ 426.4
Goodwill, Impairment Loss	418.7
Equity Method Income (Loss), Net [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other than Temporary Impairment Losses, Investments	7.1
Other Nonoperating Income (Expense) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other than Temporary Impairment Losses, Investments	13.1
Retained Earnings [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net Income (Loss) Attributable to Parent	(317.2)	185.6
Stockholders' Equity Attributable to Parent	$ 7,529.0	$ 7,265.4	7,903.6	$ 7,079.8
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			$ (7.0)

EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income [Abstract]
Net earnings attributable to Laboratory Corporation of America Holdings	$ (317.2)	$ 185.6
Shares [Abstract]
Net earnings, basic (in shares)	97.2	98.6
Dilutive effect of employee stock options and awards, (in shares)	0.0	0.9
Per Share Amount [Abstract]
Basic earnings per common share (in dollars per share)	$ (3.27)	$ 1.88
Diluted earnings per common share (in dollars per share)	$ (3.27)	$ 1.86
Net Income (Loss) Available to Common Stockholders, Diluted	$ (317.2)	$ 185.6
Weighted Average Number of Shares Outstanding, Diluted	97.2	99.5

EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Stock options (in shares)	1.3	0.3

RESTRUCTURING AND OTHER SPECIAL CHARGES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 13.2		$ 13.4
Restructuring Charges	8.8
Restructuring Reserve Settled With Cash And Other Adjustment	(25.6)
Net restructuring charges	25.4	$ 20.6
Restructuring charges related to severance and other employee costs	5.1	16.8
Other Asset Impairment Charges	4.7
Restructuring charges related to contractual obligations associated with leased facilities and other facility related costs	15.8	3.3
Employee Severance Benefits Related Restructuring Reserve Accrual Adjustment		(0.5)
Asset Impairment Charges	4.7
Operating Lease, Impairment Loss	11.6
Unused facility restructuring reserves	(0.2)
Reduction in total prior restructuring accruals	0.3
Restructuring Reserve, Current	7.8
Restructuring Reserve, Noncurrent	5.4
Covance Drug Development [Member]
Restructuring Cost and Reserve [Line Items]
Net restructuring charges	17.3	7.5
Covance Drug Development [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	4.2		5.5
Restructuring Charges	2.5
Restructuring Reserve Settled With Cash And Other Adjustment	(4.4)
Asset Impairment Charges	0.0
Operating Lease, Impairment Loss	0.0
Reduction in total prior restructuring accruals	(0.6)
Covance Drug Development [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	6.7		4.7
Restructuring Charges	2.7
Restructuring Reserve Settled With Cash And Other Adjustment	(12.2)
Asset Impairment Charges	4.7
Operating Lease, Impairment Loss	6.8
Reduction in total prior restructuring accruals	0.0
LabCorp Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Net restructuring charges	8.1	$ 13.1
LabCorp Diagnostics [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2.2		0.5
Restructuring Charges	2.1
Restructuring Reserve Settled With Cash And Other Adjustment	(0.3)
Asset Impairment Charges	0.0
Operating Lease, Impairment Loss	0.0
Reduction in total prior restructuring accruals	(0.1)
LabCorp Diagnostics [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.1		$ 2.7
Restructuring Charges	1.5
Restructuring Reserve Settled With Cash And Other Adjustment	(8.7)
Asset Impairment Charges	0.0
Operating Lease, Impairment Loss	4.8
Reduction in total prior restructuring accruals	$ (0.2)

RESTRUCTURING RESERVES (Details) - USD ($) $ in Millions	3 Months Ended
RESTRUCTURING RESERVES (Details) - USD ($) $ in Millions	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Unused facility restructuring reserves	$ 0.2
Balance, beginning of period	13.4
Restructuring charges	8.8
Reduction of prior restructuring accruals	0.3
Cash payments and other adjustments	(25.6)
Balance, end of period	13.2
Current			$ 7.8
Non-current			5.4
Total Restructuring Reserve	13.2		13.2
Employee Severance Benefits Related Restructuring Reserve Accrual Adjustment		$ 0.5
LabCorp Diagnostics [Member] \| Severance and Other Employee Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	0.5
Restructuring charges	2.1
Reduction of prior restructuring accruals	(0.1)
Cash payments and other adjustments	(0.3)
Balance, end of period	2.2
Total Restructuring Reserve	2.2		2.2
LabCorp Diagnostics [Member] \| Lease and Other Facility Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	2.7
Restructuring charges	1.5
Reduction of prior restructuring accruals	(0.2)
Cash payments and other adjustments	(8.7)
Balance, end of period	0.1
Total Restructuring Reserve	0.1		0.1
Covance Drug Development [Member] \| Severance and Other Employee Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	5.5
Restructuring charges	2.5
Reduction of prior restructuring accruals	(0.6)
Cash payments and other adjustments	(4.4)
Balance, end of period	4.2
Total Restructuring Reserve	4.2		4.2
Covance Drug Development [Member] \| Lease and Other Facility Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	4.7
Restructuring charges	2.7
Reduction of prior restructuring accruals	0.0
Cash payments and other adjustments	(12.2)
Balance, end of period	6.7
Total Restructuring Reserve	$ 6.7		$ 6.7

GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Goodwill [Line Items]
Amortization of intangibles and other assets	$ 62,300,000	$ 57,100,000
Severance Costs	5,100,000	$ 16,800,000
Intangible Assets, Gross (Excluding Goodwill)	5,811,700,000		$ 5,885,600,000
Balance as of January 1	7,865,000,000.0
Adjustments to goodwill	(54,100,000)
Balance at end of period	7,388,500,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,906,600,000		1,851,100,000
Intangible Assets, Net (Excluding Goodwill)	3,905,100,000		4,034,500,000
Goodwill, Impairment Loss	422,400,000
LabCorp Diagnostics [Member]
Goodwill [Line Items]
Goodwill and Intangible Asset Impairment	11,000,000.0
Balance as of January 1	3,721,500,000
Adjustments to goodwill	(6,600,000)
Balance at end of period	3,711,200,000
Goodwill, Impairment Loss	$ 3,700,000
Percentage Fair Value of Goodwill Exceeded Carrying Value	10.00%
Percentage Change in Discount Rate Used to Calculate Fair Value of Goodwill	1.00%
Value of Goodwill Impairment Following a Percentage Change in the Discount Rate Used to Calculate Goodwill for Reporting Unit	$ 40,000,000.0
Value of Reporting Units Goodwill Fair Value Exceeds Carrying Value	81.5
Covance Drug Development [Member]
Goodwill [Line Items]
Goodwill and Intangible Asset Impairment	426,400,000
Balance as of January 1	4,143,500,000
Adjustments to goodwill	(47,500,000)
Balance at end of period	3,677,300,000
Goodwill, Impairment Loss	$ 418,700,000
Percentage Fair Value of Goodwill Exceeded Carrying Value	10.00%
Percent Change in Discount Rate Used to Calculate Fair Value of Goodwill for Reporting Unit	1.00%
Percent of Fair Value Exceeding Carrying Value Post Percent Change in Discount Rate Used to Calculate Fair Value of Goodwill for Reporting Unit	2.00%
Value of Reporting Unit's Goodwill Following Impairment	$ 1,554,700,000
Value of Reporting Units Goodwill Fair Value Exceeds Carrying Value	631,900,000
Customer Relationships [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	4,414,400,000		4,441,700,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,371,000,000.0		1,329,500,000
Intangible Assets, Net (Excluding Goodwill)	3,043,400,000		3,112,200,000
Patents, Licenses And Technology [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444,400,000		453,600,000
Finite-Lived Intangible Assets, Accumulated Amortization	238,700,000		235,700,000
Intangible Assets, Net (Excluding Goodwill)	205,700,000		217,900,000
Noncompete Agreements [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	90,700,000		90,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	62,300,000		60,500,000
Intangible Assets, Net (Excluding Goodwill)	28,400,000		30,400,000
Trade Names [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	407,300,000		408,200,000
Finite-Lived Intangible Assets, Accumulated Amortization	228,800,000		219,900,000
Intangible Assets, Net (Excluding Goodwill)	178,500,000		188,300,000
Use Rights [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	10,800,000		10,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	5,800,000		5,500,000
Intangible Assets, Net (Excluding Goodwill)	5,000,000.0		5,400,000
Canadian licenses [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444,100,000		480,300,000
Finite-Lived Intangible Assets, Accumulated Amortization	0		0
Intangible Assets, Net (Excluding Goodwill)	444,100,000		$ 480,300,000
Trade Names [Member] \| Covance Drug Development [Member]
Goodwill [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 2,700,000

GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 5,811.7	$ 5,885.6
Accumulated Amortization	(1,906.6)	(1,851.1)
Intangible Assets, Net (Excluding Goodwill)	3,905.1	4,034.5
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	4,414.4	4,441.7
Accumulated Amortization	(1,371.0)	(1,329.5)
Intangible Assets, Net (Excluding Goodwill)	3,043.4	3,112.2
Patents, Licenses And Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444.4	453.6
Accumulated Amortization	(238.7)	(235.7)
Intangible Assets, Net (Excluding Goodwill)	205.7	217.9
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	90.7	90.9
Accumulated Amortization	(62.3)	(60.5)
Intangible Assets, Net (Excluding Goodwill)	28.4	30.4
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	407.3	408.2
Accumulated Amortization	(228.8)	(219.9)
Intangible Assets, Net (Excluding Goodwill)	178.5	188.3
Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	10.8	10.9
Accumulated Amortization	(5.8)	(5.5)
Intangible Assets, Net (Excluding Goodwill)	5.0	5.4
Canadian licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444.1	480.3
Accumulated Amortization	0.0	0.0
Intangible Assets, Net (Excluding Goodwill)	$ 444.1	$ 480.3

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 5,811.7		$ 5,885.6
Goodwill	7,388.5		7,865.0
Amortization of intangible assets	62.3	$ 57.1
Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense, 2012	176.6
Estimated amortization expense, 2013	231.8
Estimated amortization expense, 2014	225.9
Estimated amortization expense, 2015	222.8
Estimated amortization expense, 2016	218.2
Estimated amortization expense, Thereafter	2,299.9
LabCorp Diagnostics [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	3,711.2		3,721.5
Covance Drug Development [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 3,677.3		$ 4,143.5

DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details) - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Short-term Debt [Line Items]

$ 375.0

Total short-term borrowings and current portion of long-term debt

$ 417.4

415.2

Short-term borrowings and current portion of long-term debt

Short-term borrowings and the current portion of long-term debt at March 31, 2020, and December 31, 2019, consisted of the following:



	March 31, 2020			December 31, 2019
4.625% senior notes due 2020	$	415.5		$	413.7
Debt issuance costs	(0.3		)	(0.7		)
Current portion of note payable	2.2			2.2
Total short-term borrowings and current portion of long-term debt	$	417.4		$	415.2

Senior notes due 2020 [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.625%

Senior notes due 2022 [Member]

Short-term Debt [Line Items]

Senior Notes, Noncurrent

$ 500.0

DEBT (Long-term debt) (Details) - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Dec. 19, 2014

Long-term Debt [Text Block]

Long-term debt at March 31, 2020, and December 31, 2019, consisted of the following:



	March 31, 2020			December 31, 2019
3.20% senior notes due 2022	$	500.0		$	500.0
3.75% senior notes due 2022	500.0			500.0
4.00% senior notes due 2023	300.0			300.0
3.25% senior notes due 2024	600.0			600.0
3.60% senior notes due 2025	1,000.0			1,000.0
3.60% senior notes due 2027	600.0			600.0
4.70% senior notes due 2045	900.0			900.0
2.30% senior notes due 2024	400.0			400.0
2.95% senior notes due 2029	650.0			650.0
2019 Term Loan	375.0			375.0
Debt issuance costs	(41.3		)	(42.2		)
Note payable	6.5			7.0
Total long-term debt	$	5,790.2		$	5,789.8

Line of Credit Facility, Fair Value of Amount Outstanding

$ 5,790.2

$ 5,789.8

375.0

Line of Credit Facility, Maximum Borrowing Capacity

$ 1,000.0

Credit Facility Option to Increase

350.0

Credit Facility, Maximum Swing Line Borrowings

100.0

2019 Term Loan [Member]

Line of Credit Facility, Fair Value of Amount Outstanding

$ 375.0

Senior notes due 2020 [Member]

Stated interest rate percentage

4.625%

Senior notes due 2022 [Member]

Senior notes due 2023 [Member]

$ 500.0

500.0

Senior Notes, Noncurrent

500.0

Senior notes due 2025 [Member] [Member]

300.0

Senior notes due 2045 [Member]

1,000.0

Revolving Credit Facility [Member]

$ 900.0

Credit Facility, Maximum Letters of Credit

$ 150.0

Prime Rate [Member] | Revolving Credit Facility [Member]

Line of Credit Facility, Interest Rate Description

0.00% to 0.25%

2019 Term Loan [Member]